National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Jun 5, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on a type of blood cancer known as large granular lymphocytic leukemia (LGLL). Researchers want to learn more about how common this disease is and what factors might increase the risk of developing it. They will also look at how effective different treatments are, how patients respond over time, and the overall costs of healthcare for those with LGLL in China. By gathering information from a large group of patients, the study aims to improve our understanding of this condition and help develop better treatment strategies.

To participate in this trial, individuals must have a confirmed diagnosis of LGLL and have received treatment at a specific hospital since January 1, 2000. The study is open to all adults and aims to gather both medical information and personal experiences from patients. Participants can expect to share details about their health and treatment journey, and in return, their contributions could help improve care for future patients with this rare disease. It's important to note that individuals with severe health issues or substance dependence may not be eligible to join the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects diagnosed with LGLL.
• • Subjects treated at the Institute of Hematology and Blood Diseases Hospital from Jan 1, 2000.
• Exclusion Criteria:
• • Subject unlikely to be available for long-term follow-up for any reason (e.g., inability to obtain follow-up data or presence of severe comorbidities).
• • Subject with alcohol or drug dependence that may reduce their compliance with the study.
• • Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.